Why will it never be known if convalescent plasma is effective for COVID-19

Manuel Rojas; Juan Manuel Anaya

doi:10.1016/j.jtauto.2020.100069

Why will it never be known if convalescent plasma is effective for COVID-19

Manuel Rojas
, Juan Manuel Anaya

Producción científica: Contribución a revista › Artículo de revisión › revisión exhaustiva

15 Citas (Scopus)

Resumen

High expectations have been set around convalescent plasma (CP) for the treatment of COVID-19. However, none of the randomized controlled trials (RCTs) conducted so far have reached their primary endpoints. Herein we report that RCTs of CP disclose a high methodological variability in inclusion criteria, outcomes, appropriate selection of donors, dosage, concentration of neutralizing antibodies and times of transfusion. Therefore, at this time there is insufficient evidence to recommend for or against the use of CP as a treatment for COVID-19.

Idioma original	Inglés estadounidense
Número de artículo	100069
Publicación	Journal of Translational Autoimmunity
Volumen	3
DOI	https://doi.org/10.1016/j.jtauto.2020.100069
Estado	Publicada - ene 2020

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

ODS 3: Salud y bienestar

Áreas temáticas de ASJC Scopus

Inmunología
Inmulogía y alergología

Acceder al documento

10.1016/j.jtauto.2020.100069

Otros archivos y enlaces

Citar esto

@article{d94c71f28a64417dac3e3153a8fdfbed,

title = "Why will it never be known if convalescent plasma is effective for COVID-19",

abstract = "High expectations have been set around convalescent plasma (CP) for the treatment of COVID-19. However, none of the randomized controlled trials (RCTs) conducted so far have reached their primary endpoints. Herein we report that RCTs of CP disclose a high methodological variability in inclusion criteria, outcomes, appropriate selection of donors, dosage, concentration of neutralizing antibodies and times of transfusion. Therefore, at this time there is insufficient evidence to recommend for or against the use of CP as a treatment for COVID-19.",

author = "Manuel Rojas and Anaya, \{Juan Manuel\}",

note = "Funding Information: This work was supported by Universidad del Rosario (ABN-011), Bogota, Colombia. Publisher Copyright: {\textcopyright} 2020 The Authors Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",

year = "2020",

month = jan,

doi = "10.1016/j.jtauto.2020.100069",

language = "English (US)",

volume = "3",

journal = "Journal of Translational Autoimmunity",

issn = "2589-9090",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Why will it never be known if convalescent plasma is effective for COVID-19

AU - Rojas, Manuel

AU - Anaya, Juan Manuel

N1 - Funding Information: This work was supported by Universidad del Rosario (ABN-011), Bogota, Colombia. Publisher Copyright: © 2020 The Authors Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020/1

Y1 - 2020/1

N2 - High expectations have been set around convalescent plasma (CP) for the treatment of COVID-19. However, none of the randomized controlled trials (RCTs) conducted so far have reached their primary endpoints. Herein we report that RCTs of CP disclose a high methodological variability in inclusion criteria, outcomes, appropriate selection of donors, dosage, concentration of neutralizing antibodies and times of transfusion. Therefore, at this time there is insufficient evidence to recommend for or against the use of CP as a treatment for COVID-19.

AB - High expectations have been set around convalescent plasma (CP) for the treatment of COVID-19. However, none of the randomized controlled trials (RCTs) conducted so far have reached their primary endpoints. Herein we report that RCTs of CP disclose a high methodological variability in inclusion criteria, outcomes, appropriate selection of donors, dosage, concentration of neutralizing antibodies and times of transfusion. Therefore, at this time there is insufficient evidence to recommend for or against the use of CP as a treatment for COVID-19.

UR - https://www.scopus.com/pages/publications/85096882919

UR - https://www.scopus.com/pages/publications/85096882919#tab=citedBy

U2 - 10.1016/j.jtauto.2020.100069

DO - 10.1016/j.jtauto.2020.100069

M3 - Review article

C2 - 33169114

AN - SCOPUS:85096882919

SN - 2589-9090

VL - 3

JO - Journal of Translational Autoimmunity

JF - Journal of Translational Autoimmunity

M1 - 100069

ER -

Why will it never be known if convalescent plasma is effective for COVID-19

Resumen

ODS de las Naciones Unidas

Áreas temáticas de ASJC Scopus

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto